Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study.
Chemoradiotherapy
Esophageal cancer
Local control
Radiotherapy
Survival
Toxicity
Journal
Oncology research
ISSN: 1555-3906
Titre abrégé: Oncol Res
Pays: United States
ID NLM: 9208097
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
01
2023
accepted:
16
03
2023
medline:
13
6
2023
pubmed:
12
6
2023
entrez:
12
6
2023
Statut:
epublish
Résumé
The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni- and multivariable analyses. The median age of the entire cohort was 56 years (range: 26-87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and 52% of the patients received cisplatin-based concurrent chemotherapy. The 2-year OS, PFS, and LRFS rates were 58.8%, 46.9%, and 52.4%, respectively, with a median follow-up duration of 41.6 months. Patients' performance status, clinical nodal stage, tumor size, and treatment response were significant prognostic factors for OS, PFS, and LRFS in univariate analysis. Non-complete treatment response was an independent predictor for poor OS (HR = 4.41, 95% CI, 2.78-7.00,
Identifiants
pubmed: 37305394
doi: 10.32604/or.2023.028840
pii: 28840
pmc: PMC10229304
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
299-306Informations de copyright
© 2023 Guler et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest to report regarding the present study.
Références
Radiother Oncol. 2015 Aug;116(2):257-61
pubmed: 26233590
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Curr Oncol Rep. 2019 Apr 4;21(5):46
pubmed: 30949854
Clin Cancer Res. 2022 May 2;28(9):1792-1799
pubmed: 35190815
J Cancer Res Clin Oncol. 2023 Mar;149(3):1029-1041
pubmed: 35235020
Semin Radiat Oncol. 1994 Jul;4(3):179-191
pubmed: 10717106
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Dis Esophagus. 2017 Apr 1;30(4):1-10
pubmed: 28375481
Lancet Oncol. 2014 Mar;15(3):305-14
pubmed: 24556041
Head Neck. 2015 Feb;37(2):151-5
pubmed: 24347470
J Thorac Oncol. 2006 Mar;1(3):252-9
pubmed: 17409865
Am J Clin Oncol. 2010 Aug;33(4):346-52
pubmed: 19841574
Dis Esophagus. 2014 Sep-Oct;27(7):678-84
pubmed: 24147973
Lancet Oncol. 2013 Jun;14(7):627-37
pubmed: 23623280
Radiat Oncol. 2017 Jun 14;12(1):97
pubmed: 28615060
Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):735-40
pubmed: 18164844
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Arch Otolaryngol Head Neck Surg. 2000 Feb;126(2):205-8
pubmed: 10680872
Dis Esophagus. 2007;20(1):12-8
pubmed: 17227304
South Med J. 1984 Nov;77(11):1365-7
pubmed: 6494955
Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):976-984
pubmed: 27745985
Ann Oncol. 2016 Sep;27(suppl 5):v50-v57
pubmed: 27664261
Eur J Cancer. 1997 Jul;33(8):1216-20
pubmed: 9301445
J Cancer Res Clin Oncol. 2022 Sep;148(9):2567-2568
pubmed: 35697858
Ann Oncol. 2016 Sep;27(9):1664-74
pubmed: 27117535
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):656-64
pubmed: 15708243
Head Neck. 2019 Jan;41(1):146-153
pubmed: 30548508
Radiol Med. 2015 Jul;120(7):603-10
pubmed: 25644251
J Clin Oncol. 2002 Mar 1;20(5):1167-74
pubmed: 11870157